ItalyItaly

Sigma-Tau buys specialty pharmaceuticals from Enzon

12.11.2009

Rome - Sigma-Tau SpA will acquire the specialty pharmaceuticals business of Enzon Pharmaceuticals Inc for $300 million in cash and up to $27 million in potential milestones. Enzon’s specialty pharmaceutical business includes four marketed products: Abelcet, an antifungal amphotericin B liposomal injection, Adagen, an enzyme replacement therapy to treat severe combined immunodeficiency disease (SCID), and two cancer drugs, Oncaspar pegaspargase and DepoCyt Ara-C. The purchase also includes Enzon's manufacturing facility in Indianapolis, Indiana, which will be taken over by a US subsidiary of Sigma-Tau Pharmaceuticals, Inc. Enzon will receive royalties of 5 to 10 percent on incremental net sales of the four products above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products up to 2014. The transaction could be deemed to constitute a sale of “substantially all” of Enzon’s assets under Delaware law, and is therefore contingent upon approval by the holders of a majority of Enzon’s outstanding shares of common stock.
With this deal Sigma-Tau hopes to gain a better presence in the US market and to increase its standing in the field of rare diseases. The wholly Italian -owned company is based in Pomezia, near Rome. In 2008, the company achieved a turnover of €613 million. The company says a total of 13 NCEs and 12 known molecular entities in 33 different indications are currently at various stages of development. A number of these are aimed at rare diseases. Therapeutic areas in which the company's research and development are focused include metabolism, neurology, cardiovascular, oncology and immunology.

ItalyItaly

12.06.2011

Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of...

ItalyItaly

01.04.2011

Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new...

ItalyItaly

16.02.2011

Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated...

ItalyItaly

06.02.2011

Rome – The EUR2.5m ERC Advanced Grants are the Grammies of European science – not in the same league as a Nobel Prize, but still a lucrative honor. In the fourth round since 2007, the European Research Council awarded some a590m...

ItalyItaly

29.11.2010

Modena/London – Researchers from Germany, Italy and the UK have identified a molecule that is key to the onset of addiction and also involved into memory formation (EMBO Journal, doi:10.1038/emboj.2010.279). According to results...

ItalyItaly

09.11.2010

Genoa/Philadelphia — The inexpensive anti-gout drug allopurinol can counteract colorectal adenoma progression, according to data presented yesterday at the 9th Annual AACR Frontiers in Cancer Prevention Research Conference...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/browse/1/article/sigma-tau-buys-specialty-pharmaceuticals-from-enzon.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3022.0%
  • GW PHARMACEUTICALS (UK)426.00 GBP654.0%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.14 EUR-70.6%

No liability assumed, Date: 29.07.2014


Current issue

All issues

Product of the week

Products